Loading
Every dated change on the records linked to High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Bortezomib did not significantly improve four-year event-free survival for the whole group (83.
A milestone in how this cancer is treated.
Nelarabine improved disease-free survival in T-cell acute lymphoblastic leukaemia, and Capizzi methotrexate outperformed high-dose methotrexate.
A milestone in how this cancer is treated.